Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain

BACKGROUND: The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published previously...

Descripción completa

Detalles Bibliográficos
Autores principales: Weil, Arnold J., Masters, Elizabeth T., Barsdorf, Alexandra I., Bass, Almasa, Pixton, Glenn, Wilson, Jacquelyn G., Wolfram, Gernot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645978/
https://www.ncbi.nlm.nih.gov/pubmed/29041942
http://dx.doi.org/10.1186/s12955-017-0749-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645978/
https://www.ncbi.nlm.nih.gov/pubmed/29041942
http://dx.doi.org/10.1186/s12955-017-0749-y

Ejemplares similares